Kymera Therapeutics, Inc. · NASDAQ:KYMR
Ridloff Elena sold 12,000 Kymera Therapeutics, Inc. shares (Form 4)
Traded Mar 31 to Apr 1, 2026 · Filed Apr 1, 2026
From Mar 31 to Apr 1, 2026, Ridloff Elena (Director) sold 12,000 Kymera Therapeutics, Inc. shares at an average US$85.39 for US$1.02M under a trading plan, leaving 0 shares. Filed Apr 1, 2026 (Form 4).
- Sold
- 12,000 shares
- Price
- US$85.39 average (US$85.19 to US$86.05)
- Value
- US$1.02M
- Holding after
- 0 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Common Stock | Option exercise | 7,400 | US$14.18 | 7,400 | Direct |
| Mar 31, 2026 | Common Stock | Sale | 7,400 | US$85.37 | 0 | Direct |
| Apr 1, 2026 | Common Stock | Option exercise | 4,600 | US$14.18 | 4,600 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 3,400 | US$85.19 | 1,200 | Direct |
| Apr 1, 2026 | Common Stock | Sale | 1,200 | US$86.05 | 0 | Direct |
Source
Related
- Kymera Therapeutics, Inc.
- Ridloff Elena
- Kymera Therapeutics, Inc. shareholders
- Form 4 · Ridloff Elena · May 11, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026